Muhammad Syed Aun, Coath Fiona, Jegard James
Southend University Hospital, Mid and South Essex NHS Foundation Trust, Essex, UK.
Eur J Case Rep Intern Med. 2023 May 5;10(6):003742. doi: 10.12890/2023_003742. eCollection 2023.
We describe a case of remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome following administration of the ChAdOx1-S/nCoV-19 [recombinant] vaccine, suggesting a possible causal link.
A 72-year-old man presented to his general practitioner with swollen, oedematous hands and legs 2 weeks after receiving a coronavirus vaccine. He had raised inflammatory markers but remained systemically well. He was initially presumed to have cellulitis, but his symptoms persisted despite several courses of antibiotics. Deep vein thromboses, cardiac failure, renal failure and hypoalbuminaemia were ruled out. Upon Rheumatology review, he was diagnosed as having RS3PE syndrome with the Covid vaccine suspected of being an immunogenic trigger. Following initiation of steroid therapy, his symptoms improved dramatically, as is characteristic of RS3PE syndrome.
The pathophysiology of RS3PE is unclear. It is known to have various triggers and associations including infections, certain vaccines and malignancy. This case highlights that a coronavirus vaccine (ChAdOx1-S/nCoV-19 [recombinant] vaccine) is also a possible trigger. Factors that make the diagnosis likely include an acute onset of symptoms including pitting oedema in a typical distribution, age above 50, and unremarkable autoimmune serology. Other learning points from this case include the importance of antibiotic stewardship and the need to explore non-infectious causes of illness when antibiotics do not improve symptoms.
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a possible trigger of RS3PE. However, the benefits of vaccines against coronavirus outweigh the risks in the majority of patients.
This case demonstrates a possible link between the ChAdOx1-S/nCoV-19 [recombinant] vaccine and autoimmune conditions such as RS3PE.It is important to consider alternative diagnoses when antibiotic regimes fail to work.A barrier to accurate diagnosis includes an episodic approach, where a patient presents to multiple clinicians acutely rather than having a long-term, continuous relationship with a single multi-disciplinary team, where response to treatment can be monitored.
我们描述了一例在接种ChAdOx1-S/nCoV-19[重组]疫苗后出现缓解性血清阴性对称性滑膜炎伴凹陷性水肿(RS3PE)综合征的病例,提示可能存在因果关系。
一名72岁男性在接种新冠病毒疫苗2周后,双手和双腿出现肿胀、水肿,前往其全科医生处就诊。他的炎症指标升高,但全身状况良好。最初推测他患有蜂窝织炎,但尽管接受了几个疗程的抗生素治疗,症状仍持续存在。排除了深静脉血栓形成、心力衰竭、肾衰竭和低白蛋白血症。经风湿病学评估,他被诊断为RS3PE综合征,怀疑新冠疫苗是免疫原性触发因素。开始使用类固醇治疗后,他的症状显著改善,这是RS3PE综合征的特征。
RS3PE的病理生理学尚不清楚。已知它有多种触发因素和关联因素,包括感染、某些疫苗和恶性肿瘤。该病例突出表明,新冠病毒疫苗(ChAdOx1-S/nCoV-19[重组]疫苗)也是一种可能的触发因素。有助于诊断的因素可能包括症状急性发作,包括典型分布的凹陷性水肿、年龄超过50岁以及自身免疫血清学无异常。该病例的其他经验教训包括抗生素管理的重要性,以及当抗生素不能改善症状时,需要探索疾病的非感染性病因。
ChAdOx1-S/nCoV-19[重组]疫苗是RS3PE的一种可能触发因素。然而,对于大多数患者来说,新冠疫苗的益处大于风险。
该病例证明了ChAdOx1-S/nCoV-19[重组]疫苗与RS3PE等自身免疫性疾病之间可能存在联系。当抗生素治疗无效时,考虑其他诊断很重要。准确诊断的一个障碍包括间歇性就诊方式,即患者急性地向多个临床医生就诊,而不是与一个能够监测治疗反应的单一多学科团队建立长期、持续的关系。